Search research articles
Contact Us
Filters
Showing results (21-30 of 85) with videos related to
Page
of 9
Sort By:
The Journal of Urology
|
June 1, 1997
Re: Editorial comment
S L Goldenberg, M E Gleave, N Bruchovsky, et al.
Cancer Research
|
January 26, 2000
Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer
H Miyake, C Nelson, P S Rennie, et al.
Cancer Research
|
May 16, 2000
Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models
H Miyake, C Nelson, P S Rennie, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
February 10, 1999
Prostate cancer: 9. Treatment of advanced disease
M E Gleave, N Bruchovsky, M J Moore, et al.
Endocrinology
|
June 1, 2000
Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway
H Miyake, C Nelson, P S Rennie, et al.
Urology
|
June 1, 1996
Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration
S L Goldenberg, N Bruchovsky, M E Gleave, et al.
International Journal of Cancer
|
March 29, 2001
Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model
S Leung, H Miyake, T Zellweger, et al.
Urology
|
December 22, 1999
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides
M E Gleave, H Miayake, J Goldie, et al.
The Prostate
|
July 6, 2000
Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors
S Y Leung, J Jackson, H Miyake, et al.
Journal of Cellular Biochemistry
|
May 15, 1998
Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model
M E Gleave, N Sato, M Sadar, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 85) with videos related to
Sort By:
Page
of 9
The Journal of Urology
|
June 1, 1997
Re: Editorial comment
S L Goldenberg, M E Gleave, N Bruchovsky, et al.
Cancer Research
|
January 26, 2000
Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer
H Miyake, C Nelson, P S Rennie, et al.
Cancer Research
|
May 16, 2000
Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models
H Miyake, C Nelson, P S Rennie, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
February 10, 1999
Prostate cancer: 9. Treatment of advanced disease
M E Gleave, N Bruchovsky, M J Moore, et al.
Endocrinology
|
June 1, 2000
Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway
H Miyake, C Nelson, P S Rennie, et al.
Urology
|
June 1, 1996
Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration
S L Goldenberg, N Bruchovsky, M E Gleave, et al.
International Journal of Cancer
|
March 29, 2001
Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model
S Leung, H Miyake, T Zellweger, et al.
Urology
|
December 22, 1999
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides
M E Gleave, H Miayake, J Goldie, et al.
The Prostate
|
July 6, 2000
Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors
S Y Leung, J Jackson, H Miyake, et al.
Journal of Cellular Biochemistry
|
May 15, 1998
Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model
M E Gleave, N Sato, M Sadar, et al.
Page
of 9